| Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077] | Technology appraisal guidance |
| Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304] | Technology appraisal guidance |
| Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157] | Technology appraisal guidance |
| Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158] | Technology appraisal guidance |
| Tocilizumab for treating systemic sclerosis [ID1396] | Technology appraisal guidance |
| Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406] | Technology appraisal guidance |
| Tovorafenib for Glioma (rare disease) [ID6557] | Technology appraisal guidance |
| Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509] | Technology appraisal guidance |
| Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer [TSID11910] | Technology appraisal guidance |
| Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511] | Technology appraisal guidance |
| Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226] | Technology appraisal guidance |
| Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [TSID12104] | Technology appraisal guidance |
| Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540] | Technology appraisal guidance |
| Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772] | Technology appraisal guidance |
| Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891] | Technology appraisal guidance |
| Troriluzole for spinocerebellar ataxia [ID6456] | Technology appraisal guidance |
| Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402] | Technology appraisal guidance |
| Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781] | Technology appraisal guidance |
| UX111 for treating mucopolysaccharidosis type IIIA [ID6540] | Technology appraisal guidance |
| Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806] | Technology appraisal guidance |
| Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468] | Technology appraisal guidance |
| Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879] | Technology appraisal guidance |
| Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295] | Technology appraisal guidance |
| Vilobelimab for treating COVID 19 [TSID11815] | Technology appraisal guidance |
| Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807] | Technology appraisal guidance |